US2020181092A1PendingUtilityA1

5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

Assignee: OTSUKA PHARMA CO LTDPriority: Mar 4, 2016Filed: Feb 12, 2020Published: Jun 11, 2020
Est. expiryMar 4, 2036(~9.6 yrs left)· nominal 20-yr term from priority
C07D 237/14C07D 237/02A61P 35/00A61K 31/50C07D 237/04
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.

Claims

exact text as granted — not AI-modified
1 . A compound of formula (1): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof 
         wherein
 R 1  to R 4  are independently hydrogen atom, halogen, OH, CN, C 1-6  alkyl group, halogenated C 1-6  alkyl group, C 2-6  alkenyl group, C 1-6  alkoxy group, or halogenated C 1-6  alkoxy group, provided that one or two of R 1  to R 4  are hydrogen atoms, but it is not that all of three or four thereof are hydrogen atoms, and 
 Y is C 1-6  alkylene or C 2-6  alkenylene group, wherein the alkylene or alkenylene group may be substituted with one or more substituents selected independently from the group consisting of C 1-6  alkyl group, halogen, and halogenated C 1-6  alkyl group, further wherein a substitutable carbon atom in the substituent bonding to the alkylene or alkenylene group and another substitutable carbon atom in the alkylene or alkenylene group, or two substitutable carbon atoms in the substituent bonding to the alkylene or alkenylene group may be combined together to form a 3- to 6-membered carbon ring. 
 
       
     
     
         2 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein any two of R 1  to R 4  are hydrogen atoms. 
     
     
         3 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein R 1  to R 4  are independently hydrogen atom, halogen, OH, CN, C 1-4  alkyl group, halogenated C 1-4  alkyl group, C 2-4  alkenyl group, C 1-4  alkoxy group, or halogenated C 1-4  alkoxy group. 
     
     
         4 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein R 1  to R 4  are independently hydrogen atom, fluorine atom, chlorine atom, OH, CN, C 1-4  alkyl group, vinyl group, or C 1-4  alkoxy group. 
     
     
         5 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein the alkylene or alkenylene group in Y is substituted with one or more substituents selected independently from the group consisting of C 1-4  alkyl group, halogen, and halogenated C 1-4  alkyl group, further wherein a substitutable carbon atom in the substituent bonding to the alkylene or alkenylene group and another substitutable carbon atom in the alkylene or alkenylene group, or two substitutable carbon atoms in the substituent bonding to the alkylene or alkenylene group may be combined together to form a 3- to 6-membered carbon ring. 
     
     
         6 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein a carbon atom of the alkylene or alkenylene group in Y is substituted with one or two substituents selected independently from the group consisting of C 1-4  alkyl group and halogenated C 1-4  alkyl group, further when the carbon atom is substituted with two substituents, each substitutable carbon atom in the two substituents may be combined together to form a 3- to 6-membered carbon ring. 
     
     
         7 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein the alkylene or alkenylene group in Y has no substituent. 
     
     
         8 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, wherein the compound of formula (1) is represented in the following formula: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof, which is selected from the following compounds:
 Example 1: 6-[3-bromo-5-chloro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 2: 6-[3,5-dichloro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 7: 6-[3-chloro-5-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 12: 6-[3-bromo-2-fluoro-4-(3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 19: 6-[3-chloro-2-fluoro-4-(3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 22: 6-[3-chloro-2-fluoro-4-(3-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 24: 6-[3-bromo-2-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 26: 6-[3-bromo-5-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 31: 6-[3-chloro-4-(2-hydroxy-2-methylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 36: 6-[3-chloro-2-fluoro-4-(2-hydroxy-2-methylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 40: 6-{3-chloro-4-[(2R)-2-hydroxypropoxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 44: 6-{3-chloro-4-[(1-hydroxycyclopropyl)methoxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 47: 6-{3-chloro-2-fluoro-4-[(1-hydroxycyclopropyl)methoxy]phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 48: 6-[3-bromo-2-fluoro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 53: 6-[3,5-dichloro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 54: 6-[3-chloro-2-fluoro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 55: 6-[3-chloro-4-(2-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 57: 6-[3-bromo-5-chloro-4-(2-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 59: 6-[2-fluoro-4-(2-hydroxypropoxy)-3-vinylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 64: 6-[3-chloro-2-fluoro-4-(2-hydroxybutoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 69: 6-[3-bromo-5-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 72: 6-[3-chloro-4-(3-hydroxy-2,2-dimethylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 99: 6-[3-chloro-5-fluoro-4-(4-hydroxy-2,2-dimethylbutoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 100: 6-[3,5-dichloro-4-(4-hydroxy-2,2-dimethylbutoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 109: 6-[3,5-dichloro-4-(2,2-difluoro-3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 112: 6-[3-bromo-4-(2,2-difluoro-3-hydroxypropoxy)-2-fluorophenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 113: 6-[3-chloro-4-(2,2-difluoro-3-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 118: (5R)-(−)-6-[3-chloro-2-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 120: (5R)-(−)-6-[4-(2,2-difluoro-3-hydroxypropoxy)-2-fluoro-3-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 124: (5R)-(−)-6-[2,3-difluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 125: (5R)-(−)-6-[3-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 127: (5R)-(−)-6-[3-bromo-5-chloro-4-(3-hydroxy-2,2-dimethylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 131: 6-[3-chloro-2,5-difluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 137: 6-[3-chloro-2-fluoro-4-(3-hydroxy-2,2-dimethylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 140: 6-[3-chloro-2,5-difluoro-4-(3-hydroxypropoxy)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 142: 6-[3-chloro-4-(3-hydroxy-2-methylpropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 148: 6-[3-chloro-2-fluoro-4-(2-hydroxypropoxy)-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 151: 6-{3-chloro-2-fluoro-4-[(Z)-4-hydroxy-2-butenyloxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 155: 6-(3-chloro-4-{[(1S*,2R*)-2-(hydroxymethyl)cyclopropyl]methoxy}-5-methylphenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 159: 6-[3-chloro-4-(2,2-difluoro-3-hydroxypropoxy)-2-fluoro-5-methylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 160: 6-[4-(2,2-difluoro-3-hydroxypropoxy)-2-fluoro-3,5-dimethylphenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 167: 6-{3-chloro-2-fluoro-4-[(1-hydroxycyclopropyl)methoxy]-5-methylphenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 168: 6-{3-bromo-2-fluoro-4-[(1-hydroxycyclopropyl)methoxy]phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, 
 Example 170: 6-{3,5-dichloro-4-[(1-hydroxycyclopropyl)methoxy]phenyl}-5-methyl-4,5-dihydro-2H-pyridazin-3-one, and 
 Example 184: 6-[2-fluoro-4-(2-hydroxy-2-methylpropoxy)-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one. 
 
     
     
         10 . An agent for treating malignant tumor, comprising the compound of  claim 1  or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2020181092A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.